8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

      Date of Report (Date of Earliest Event Reported): September 26, 2002

                               VENTIV HEALTH, INC.

             (Exact Name of Registrant as Specified in its Charter)

                                    DELAWARE
                 (State or Other Jurisdiction of Incorporation)

             0-30318                                     52-2181734
- -------------------------------------       ------------------------------------
     (Commission File Number)               (I.R.S. Employer Identification No.)

                          c/o VENTIV HEALTH U.S. SALES
                               VANTAGE COURT NORTH
                               200 COTTONTAIL LANE
                           SOMERSET, NEW JERSEY 08873
               (Address of Principal Executive offices) (Zip Code)

                                 (800) 416-0555
               (Registrant's Telephone Number, Including Area Code

                                       N/A
          (Former Name or Former Address, if changed Since Last Report)



                               Ventiv Health, Inc.
                           CURRENT REPORT ON fORM 8-k

Item 5. Other Material Events

         On September 26, 2002 and October 16, 2002, the Company completed the
sale of its Germany and United Kingdom ("U.K.") based contract sales business
units, respectively, as more fully discussed below.

         On September 26, 2002 and effective September 30, 2002, the Company
completed the sale of 100% of the shares of Ventiv Health Germany GmbH (the
holding company for the subsidiaries comprising the Ventiv Health Germany
operating unit) to a group of management purchasers, lead by the managing
director of that business. In consideration for the sale, the Company received
$6.2 million at closing, and shall receive additional consideration of $5.0
million payable from future earnings of the business. The business will continue
to operate under the name "Ventiv Health Germany" for a period of up to three
(3) years. The Company shall also provide ongoing assistance, business referrals
and other consultancy services for a period of three (3) years, for which it
expects to receive total compensation of $0.8 million over term of the related
agreement.

         On October 16, 2002, the Company completed the sale of the assets and
business of its Ventiv Health U.K. operating unit to Ireland-based United Drug
plc. Total consideration of $7.5 million was satisfied in cash and received in
full on completion of transaction.

Exhibits

99.1 Press Release dated October 17, 2002 completing the sale of the Company's
Germany-based contract sales business unit

99.2 Press Release dated October 17, 2002 completing the sale of the Company's
United Kingdom ("U.K.")-based contract sales business unit

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                               VENTIV HEALTH, INC.

                               By: /s/ John R. Emery
                                   --------------------------------------------
Date: October 21, 2002             Name: John R. Emery
                                   Title: Chief Financial Officer
                                   (Principal Accounting and Financial Officer)

EX-99.1

                                                                    EXHIBIT 99.1

Ventiv Health, Inc. Completes Sale of German-Based CSO Business

SOMERSET, N.J., Oct 17, 2002 Ventiv Health, Inc. (Nasdaq: VTIV) today announced
that it has completed the sale of its German-based Contract Sales Organization
(CSO) in a management buy-out transaction. The Company is to receive total
consideration of up to $12.0 million, $6.2 million of which was paid at closing
with the balance payable from future earnings of the business.

Mr. Eran Broshy, CEO of Ventiv Health, stated, "We are pleased to have completed
the sale of our German-based CSO business. As communicated in our most recent
quarterly press release, we adopted a plan to explore the divestiture of our
European CSO businesses, in order to focus our resources on our U.S.-based
contract sales and analytics businesses which we believe offer greater potential
for growth. The sale of our German business represents the first completed step
in this plan of divestiture."

Ms. Andrea von Beckerath, former General Manager of Ventiv Health-Germany and
now purchaser of this business, said, "I am very pleased to have completed the
acquisition of Ventiv Health's German-based CSO business. We will retain the
Ventiv Health name, which is well-recognized in Germany, and will continue to
work closely with Ventiv on cross-border opportunities where appropriate. Our
management team and financial backers are highly confident that we can continue
to grow this business successfully in the coming years."

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv Health's
performance to differ materially. Such risks include, without limitation:
changes in trends in the pharmaceutical industry or in pharmaceutical
outsourcing; our ability to compete successfully with other services in the
market; our ability to maintain large client contracts or to enter into new
contracts; uncertainties related to future incentive payments; and, our ability
to operate successfully in new lines of business. Readers of this press release
are referred to documents filed from time to time by Ventiv Health Inc. with the
Securities and Exchange Commission for further discussion of these and other
factors.

SOURCE Ventiv Health, Inc.

CONTACT:
Investors - Corporate: - John Emery, CFO of Ventiv Health, Inc.,
1-732-537-4800, investor@ventiv.com

EX-99.2

                                                                    EXHIBIT 99.2

Ventiv Health, Inc. Completes Sale of United Kingdom-Based CSO Business To
United Drug Plc

SOMERSET, N.J., Oct 17, 2002 Ventiv Health, Inc. (Nasdaq: VTIV) today announced
that it has completed the divestiture of its United Kingdom-based Contract Sales
Organization (CSO) business to Ireland-based United Drug plc (ISE: UDG.I; LSE:
UDG.L). Total consideration for the purchase was $7.5 million (Stg 4.8 million
pounds sterling), which was satisfied in cash and paid in full on completion of
the transaction.

Mr. Eran Broshy, CEO of Ventiv, stated, "We are pleased to have completed the
sale of our U.K.-based CSO business. As communicated in our most recent
quarterly press release, we adopted a plan to explore the divestiture of our
European CSO businesses, in order to focus our resources on our U.S.-based
contract sales and analytics businesses, which we believe offer greater
potential for growth. The successful completion of the sale of our U.K. business
demonstrates the substantial progress we have made in executing this strategy."

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv Health's
performance to differ materially. Such risks include, without limitation:
changes in trends in the pharmaceutical industry or in pharmaceutical
outsourcing; our ability to compete successfully with other services in the
market; our ability to maintain large client contracts or to enter into new
contracts; uncertainties related to future incentive payments; and, our ability
to operate successfully in new lines of business. Readers of this press release
are referred to documents filed from time to time by Ventiv Health Inc. with the
Securities and Exchange Commission for further discussion of these and other
factors.

SOURCE Ventiv Health, Inc.

CONTACT:
Investors - Corporate, John Emery, CFO of Ventiv Health, Inc.,
1-732-537-4800,
or investor@ventiv.com